Genetics Can Make a Ten-Year Difference in the Onset of Alzheimer’s Disease
Why do some people develop Alzheimer’s disease much earlier than others, even when they share the same genetic alteration that causes the disease? An international study co-led by the Institut de Recerca Sant Pau (IR Sant Pau) has identified genetic factors that help explain these differences. The findings show that the combination of certain genetic variants can make a difference of up to a decade in the age of Alzheimer’s onset in individuals with an extra copy of the APP gene, both with and without Down syndrome.
The research, published in the journal Alzheimer’s & Dementia, analyzed clinical and genetic data from 1,057 individuals. Of these, 957 had Down syndrome, while the other 100 carried a specific duplication of the APP gene, located on chromosome 21, which, when duplicated, causes a rare form of early-onset hereditary Alzheimer’s disease.
The study’s authors include Danna Perlaza, a researcher in the Molecular Neurodegeneration Research Group at IR Sant Pau and co-first author of the article; Dr. Olivia Belbin, head of the Molecular Neurodegeneration Research Group at IR Sant Pau; and Dr. Oriol Dols-Icardo, a researcher in the Neurobiology of Dementia Research Group at IR Sant Pau. The latter two are listed as senior investigators on the study, and all three are members of the Memory Unit at Hospital de Sant Pau.
The Same Genetic Alteration, Different Ages of Onset
The APP gene contains the instructions for producing amyloid precursor protein, from which the beta-amyloid peptide is generated. The accumulation of this peptide in the brain is one of the main characteristics of Alzheimer’s disease. Having an extra copy of this gene increases its production and promotes the development of the disease at relatively early ages.
This occurs in people with Down syndrome, who generally have three copies of chromosome 21, as well as in individuals who carry a specific duplication of the region containing the APP gene without having Down syndrome. However, the age at which the first signs of Alzheimer’s appear varies considerably among these individuals, typically between 40 and 65 years of age. Until now, the factors responsible for much of this variability have not been sufficiently understood.
“We knew that having an extra copy of the APP gene is directly related to the development of Alzheimer’s disease, but we did not fully understand why some people experience their first symptoms much earlier than others. Our findings show that other genetic variants, which also influence sporadic Alzheimer’s disease, help explain these differences,” says Danna Perlaza.
To investigate this question, the team analyzed the effect of the APOE gene, one of the main genetic factors associated with Alzheimer’s disease, along with 77 other genetic variants linked to the risk of developing the disease. These variants were combined into a genetic risk score that makes it possible to assess the cumulative effect of multiple variants, each of which may have a relatively small influence.
The results indicated that the APOE ε2 allele is associated with a later onset of Alzheimer’s disease, whereas APOE ε4 and a higher burden of genetic risk variants are associated with earlier onset. These effects were observed across all participants, with similar patterns in both groups studied.
An Estimated Difference of Up to a Decade
One of the most significant findings of the research is the magnitude of these differences. By combining information from the APOE gene with the genetic risk score, the researchers estimated that the median age of Alzheimer’s onset could vary by approximately ten years between individuals with the lowest-risk and highest-risk genetic profiles.
Among individuals with an APP gene duplication, the estimated median age of onset was 49.4 years for the highest-risk profile and 58.8 years for the lowest-risk profile, representing a difference of 9.4 years. In the group with Down syndrome, the corresponding ages were 50.1 and 60.1 years, respectively, a difference of ten years.
These figures are derived from statistical models comparing extreme genetic profiles and do not mean that it is currently possible to predict precisely the age at which a particular individual will develop Alzheimer’s disease. Nevertheless, they highlight the importance of considering other genetic factors beyond the alteration that causes the disease.
“What is interesting is that a genetic alteration with such a substantial effect as having an extra copy of APP does not completely determine when the disease will manifest. The combination of other genetic variants can substantially modify its course. This helps us better understand the complexity of Alzheimer’s disease and identify factors that could be useful in anticipating its onset,” explains Dr. Olivia Belbin.
The researchers also examined the biological mechanisms associated with these variants. The findings particularly highlighted pathways involved in beta-amyloid metabolism and angiogenesis, the process through which new blood vessels form. In individuals with Down syndrome, an association was also identified with endocytosis, a mechanism by which cells take up substances from their surroundings.
These findings suggest that processes related to amyloid metabolism and vascular biology may play a particularly important role in determining when the disease manifests.
Furthermore, the analysis found no significant association between the age of Alzheimer’s onset and the size of the APP gene duplication, or with the presence of other duplicated genes on chromosome 21 examined in the study.
Toward More Personalized Alzheimer’s Prevention
The findings provide valuable information for understanding the progression of Alzheimer’s disease in people with Down syndrome and carriers of APP duplications, two populations that are particularly significant for investigating the early mechanisms of the disease.
In both cases, the existence of a known genetic cause makes it possible to study how Alzheimer’s develops and which factors may modify its progression. Identifying genetic variants associated with earlier or later onset could help improve participant selection and the timing of interventions in future preventive clinical trials.
“One of the major challenges in Alzheimer’s research is to intervene before symptoms appear, when the disease may already have been developing in the brain for years. This study reminds us that even individuals with a known genetic cause do not necessarily follow the same disease course. Understanding what determines these differences is essential for moving toward more effective prevention,” emphasizes Dr. Oriol Dols-Icardo.
The authors emphasize that further research is still needed before these findings can be translated into clinical practice. Among other questions, it will be important to determine whether the identified variants also influence when Alzheimer’s biomarkers begin to change and to assess the extent to which incorporating this genetic information improves individual predictions.
The study also reinforces the idea that genetically determined forms of Alzheimer’s disease and sporadic Alzheimer’s share essential biological mechanisms. Understanding how these factors interact may provide new insights into the disease and contribute to the development of future strategies aimed at delaying its onset.
Reference Article:
Groeneveld J, Perlaza D, Olivé C, Grangeon L, Tesi N, Nicolas A, Jiang C, de Rojas I, Wallon D, Rousseau S, Rovira M, de Asúa DR, Moldenhauer F, Mu R, Cassinari K, Zarea A, Escabias JA, Lambert J-C, Pijnenburg YAL, Hulsman M, Vijverberg EGB, Levin J, Jucker M, McDade E, Fortea J, Holstege H, Duits FH, Vermunt L, Patel M, Johnson M, Renton AE, Goate AM, Cruchaga C, Pottier C, Fernandez MV, Belbin O, Nicolas G, Dols-Icardo O, van der Lee SJ, Dominantly Inherited Alzheimer Network. APOE and genetic risk variants influence Alzheimer’s disease onset in carriers of an extra copy of APP, with and without Down syndrome. Alzheimers Dement 2026;22:e71738. https://doi.org/10.1002/alz.71738.